Abstract
Of the 61 newly diagnosed patients with Bence-Jones (BJ) myeloma presenting to our centre between May 1986 and December 1997, 53 received sequential therapy (ST) comprising infusional chemotherapy (IC) followed by high-dose therapy and autotransplantation with interferon-α2b maintenance. The outcome was compared with 153 IgG and 39 IgA similarly treated myeloma patients. Response to IC and high-dose was comparable between the three subtypes but a significantly higher proportion of patients with BJ myeloma failed to receive high-dose compared to IgG (P = 0.003) and IgA (P = 0.04) myeloma. Median overall survival (OS) of patients with BJ myeloma (2.8 years) and event-free survival (EFS, 1.2 years) was significantly shorter than for patients with IgG myeloma (4.5 years, P = 0.03 and 2.1 years, P = 0.03, respectively). However, among those patients who achieved complete remission there was no difference in OS and EFS between IgG and BJ myeloma. In distinction to IgG myeloma where age and β2M were significant, Cox analysis on presentation features identified performance status and urine total protein as having significant impact on OS. We conclude that achieving CR is an important treatment aim in patients with BJ myeloma, conferring a similar outlook on survival as in patients with the IgG subtype, and there is a need to consider different subtype-specific staging systems when evaluating the results of published or ongoing therapeutic trials. Bone Marrow Transplantation (2001) 28, 29–37.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Powles R, Raje N, Milan S et al. Outcome assessment of a population based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment Bone Marrow Transplant 1997 20: 435–443
Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood 1999 93: 55–65
Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome New Engl J Med 1996 335: 91–97
Bjorkstrand BB, Ljungman P, Svensson H et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case matched study from the European Group for Blood and Marrow Transplantation Blood 1996 88: 4711–4718
Kulkarni S, Powles RL, Treleaven JG et al. Impact of previous high-dose therapy on outcome after allografting for multiple myeloma Bone Marrow Transplant 1999 23: 675–680
Sirohi B, Powles R, Mehta J et al. Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system Br J Haematol 1999 107: 656–666
Forgeson GV, Selby P, Lakhani S et al. Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients Br J Cancer 1988 58: 469–473
Raje N, Powles R, Kulkarni S et al. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma Br J Haematol 1997 97: 153–160
Gore ME, Selby PJ, Millar B et al. The use of verapamil to overcome drug resistance in myeloma Proc Am Soc Clin Oncol 1988 7: 228
Cunningham D, Paz-Ares L, Milan S et al. High dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma J Clin Oncol 1994 12: 759–736
Raje N, Powles R, Horton C et al. Comparison of marrow vs blood derived stem cells for autografting in previously untreated multiple myeloma Br J Cancer 1997 75: 1684–1689
Kulkarni S, Powles R, Treleaven J et al. Randomized trial of equal doses of lenograstim and filgrastim for mobilisation of peripheral blood stem cells in patients with hematologic malignancies Bone Marrow Transplant 2000 25: S260
Cunningham D, Powles RL, Malpas J et al. A randomised trial of maintenance interferon following high dose chemotherapy in multiple myeloma; long term follow up results Br J Haematol 1998 102: 495–502
Kohn J, Riches PG . A cellulose acetate immuno-fixation technique J Immunolog Meth 1978 20: 325–331
Karinkanta HH, Nieminen EJ . An improved technique for immunofixation of electropherograms Clin Chem 1978 24: 1639–1641
Watanaba N, Kamel S, Ohkubo A et al. Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer Clin Chem 1986 328: 1551–1554
Gore ME, Selby PJ, Viner C et al. Intensive treatment of multiple myeloma and criteria for complete remission Lancet 1989 2: 879–881
Kruskal WH, Wallis WA . Use of ranks in one-criterion variance analysis J Am Stat Assoc 1952 47: 583–621
Kaplan EL, Meier P . Non parametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481
Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples Br J Cancer 1977 35: 1–39
Cox DR . Regression models and life tables J Roy Stat Soc Br 1972 24: 187–220
BMDP statistical software release 7 . BMDP Statistical Software Manual University of California Press: Berkeley 1992 pp 825–866
Durie BGM, Salmon SE . A clinical staging system for multiple myeloma Cancer 1975 36: 842–854
Hobbs JR . Immunoglobulins in clinical chemistry Adv Clin Chem 1971 14: 219–317
Cunningham D, Paz-Ares L, Gore ME et al. High dose melphalan for multiple myeloma: long term follow up data J Clin Oncol 1994 12: 764–768
Sirohi B, Powles R, Treleaven J et al. Light chain disease (LCD): a different form of myeloma compared with IgG disease Blood 1999 10: (Suppl. 1) 2567
Smolens P, Barnes JL, Kreisberg R . Hypercalcemia can potentiate the nephrotoxicity of Bence Jones proteins J Lab Clin Med 1987 110: 460–465
Howells DPM . Serum albumin and survival in myelomatosis Br Med J 1971 3: 583
McElwain TJ, Powles R . High dose intravenous melphalan for plasma cell leukaemia and myeloma Lancet 1983 2: 822–824
Jagannath S, Barlogie B, Dicke K et al. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors Blood 1990 76: 1860–1866
Sirohi B, Powles R, Kulkarni S et al. Glomerular filtration rate (GFR) as a surrogate marker for transplant-related toxicity and overall outcome in patients of multiple myeloma (MM) homogenously treated with high dose melphalan (HDM) 200/m2 Bone Marrow Transplant 2000 25: (Suppl. 1) 694
Merlini G, Waldenstrom JG, Jayakar S . A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients Blood 1980 55: 1011–1019
Medical Research Council Working Party on Leukemia in adults . Prognostic features in the third MRC myelomatosis trial Br J Cancer 1980 42: 831–840
Acknowledgements
We thank the David Adams Leukaemia Fund, Bud Flanagan Leukaemia Fund and the Institute of Cancer Research.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sirohi, B., Powles, R., Kulkarni, S. et al. Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplant 28, 29–37 (2001). https://doi.org/10.1038/sj.bmt.1703093
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703093
Keywords
This article is cited by
-
MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival
Biology Direct (2011)
-
Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients
Bone Marrow Transplantation (2003)